Executives at drug company Actavis knew they had to move fast to avoid a plunge in sales of their top-selling drug, Namenda, a treatment for Alzheimer’s disease that would lose patent protection in July. When that happened, generic knockoffs would flood the market, and doctors and pharmacists could switch patients to the lower-cost equivalents. Jerry Avorn, professor of medicine at Brigham and Women’s Hospital, is quoted.
